PHAS
PhaseBio Pharmaceuticals, Inc. Common Stock
PHAS
PHAS
Delisted
PHAS was delisted on the 2nd of November, 2022.
51 hedge funds and large institutions have $118M invested in PhaseBio Pharmaceuticals, Inc. Common Stock in 2019 Q4 according to their latest regulatory filings, with 11 funds opening new positions, 14 increasing their positions, 16 reducing their positions, and 18 closing their positions.
New
Increased
Maintained
Reduced
Closed
more capital invested
Capital invested by funds: $ → $
less funds holding
Funds holding: →
less repeat investments, than reductions
Existing positions increased: | Existing positions reduced:
less first-time investments, than exits
New positions opened: | Existing positions closed:
Holders
51
Holding in Top 10
1
Calls
–
Puts
–
Top Buyers
| 1 | +$2.75M | |
| 2 | +$1.17M | |
| 3 | +$1.07M | |
| 4 |
BlackRock
New York
|
+$487K |
| 5 |
ECM
ExodusPoint Capital Management
New York
|
+$111K |
Top Sellers
| 1 | -$3.4M | |
| 2 | -$1.78M | |
| 3 | -$440K | |
| 4 |
Morgan Stanley
New York
|
-$299K |
| 5 |
Millennium Management
New York
|
-$250K |